Anti-Hypertensive Drugs - Mexico

Mexico

In Mexico, the revenue in the Anti-Hypertensive Drugs market is forecasted to reach US$140.70m by the year 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of -0.31%, leading to a market volume of US$138.50m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$12,290.00m in 2024.
The demand for anti-hypertensive drugs in Mexico is rising due to the country's high prevalence of hypertension and the aging population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Mexico has been experiencing a steady growth in recent years, driven by various factors such as increasing prevalence of hypertension, aging population, and changing lifestyles.

Customer preferences: Mexican customers have been showing a preference towards generic drugs due to their affordability and availability. This has led to an increase in the production and consumption of generic anti-hypertensive drugs in the country. However, there is also a growing demand for branded drugs, especially among the middle and upper class population who are willing to pay more for premium quality and efficacy.

Trends in the market: The Mexican government has been promoting the use of generic drugs through various initiatives such as the “Seguro Popular” program, which provides free or subsidized healthcare to low-income families. This has led to an increase in the demand for generic anti-hypertensive drugs, as they are more cost-effective than branded drugs. Additionally, there has been a growing trend towards the use of combination therapies, which involve the use of two or more drugs to treat hypertension. This has led to an increase in the production and consumption of fixed-dose combination drugs in the country.

Local special circumstances: Mexico has a large population of overweight and obese individuals, which is a major risk factor for hypertension. This has led to a high prevalence of hypertension in the country, with over 30% of the adult population being affected. Additionally, there is a lack of awareness and education about hypertension among the general population, which has led to a low diagnosis and treatment rate. This presents a significant opportunity for pharmaceutical companies to expand their market by increasing awareness and education about hypertension and its treatment.

Underlying macroeconomic factors: Mexico has a rapidly growing economy, with a large and expanding middle class population. This has led to an increase in healthcare spending and a growing demand for high-quality healthcare services. Additionally, the aging population in the country has led to an increase in the prevalence of chronic diseases such as hypertension, which has further fueled the growth of the anti-hypertensive drugs market. However, the market is also facing challenges such as increasing competition from low-cost generic drugs and stringent regulations imposed by the government.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.